JP2006523672A - トリグリセリド及びコレステロールの蓄積に結びつけられる疾病の治療方法 - Google Patents
トリグリセリド及びコレステロールの蓄積に結びつけられる疾病の治療方法 Download PDFInfo
- Publication number
- JP2006523672A JP2006523672A JP2006506481A JP2006506481A JP2006523672A JP 2006523672 A JP2006523672 A JP 2006523672A JP 2006506481 A JP2006506481 A JP 2006506481A JP 2006506481 A JP2006506481 A JP 2006506481A JP 2006523672 A JP2006523672 A JP 2006523672A
- Authority
- JP
- Japan
- Prior art keywords
- mice
- aminoisobutyric acid
- human
- treatment
- baiba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 74
- 150000003626 triacylglycerols Chemical class 0.000 title claims abstract description 68
- 238000009825 accumulation Methods 0.000 title claims abstract description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims description 176
- 235000012000 cholesterol Nutrition 0.000 title claims description 78
- 201000010099 disease Diseases 0.000 title description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 11
- 238000011282 treatment Methods 0.000 claims abstract description 83
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 37
- 239000002207 metabolite Substances 0.000 claims abstract description 35
- 239000000651 prodrug Substances 0.000 claims abstract description 32
- 229940002612 prodrug Drugs 0.000 claims abstract description 32
- 230000006806 disease prevention Effects 0.000 claims abstract description 13
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims abstract description 12
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 claims description 344
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 60
- 210000000577 adipose tissue Anatomy 0.000 claims description 59
- 210000004185 liver Anatomy 0.000 claims description 58
- 241001465754 Metazoa Species 0.000 claims description 55
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 38
- 102000004877 Insulin Human genes 0.000 claims description 30
- 108090001061 Insulin Proteins 0.000 claims description 30
- 239000013543 active substance Substances 0.000 claims description 30
- 229940125396 insulin Drugs 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 208000008589 Obesity Diseases 0.000 claims description 23
- 235000020824 obesity Nutrition 0.000 claims description 22
- 208000004930 Fatty Liver Diseases 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 20
- 102000011690 Adiponectin Human genes 0.000 claims description 19
- 108010076365 Adiponectin Proteins 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 206010022489 Insulin Resistance Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 16
- 235000016709 nutrition Nutrition 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000009467 reduction Effects 0.000 claims description 13
- 206010020772 Hypertension Diseases 0.000 claims description 12
- 230000036765 blood level Effects 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 230000002950 deficient Effects 0.000 claims description 7
- 230000035945 sensitivity Effects 0.000 claims description 7
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 231
- 238000002474 experimental method Methods 0.000 description 56
- 150000002632 lipids Chemical class 0.000 description 53
- 235000021068 Western diet Nutrition 0.000 description 46
- 235000000891 standard diet Nutrition 0.000 description 42
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 39
- 108010010234 HDL Lipoproteins Proteins 0.000 description 37
- 102000015779 HDL Lipoproteins Human genes 0.000 description 37
- 230000000694 effects Effects 0.000 description 35
- 230000002829 reductive effect Effects 0.000 description 25
- 230000009286 beneficial effect Effects 0.000 description 23
- 239000003651 drinking water Substances 0.000 description 23
- 235000020188 drinking water Nutrition 0.000 description 23
- 238000005259 measurement Methods 0.000 description 23
- 206010016654 Fibrosis Diseases 0.000 description 12
- 230000007863 steatosis Effects 0.000 description 12
- 108010092277 Leptin Proteins 0.000 description 11
- 230000035508 accumulation Effects 0.000 description 11
- 150000003904 phospholipids Chemical class 0.000 description 11
- 102000016267 Leptin Human genes 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 230000004761 fibrosis Effects 0.000 description 10
- 235000021588 free fatty acids Nutrition 0.000 description 10
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 10
- 229940039781 leptin Drugs 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 206010028851 Necrosis Diseases 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000013116 obese mouse model Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003240 portal vein Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- -1 trifluoroacetic acid Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- MZFOKIKEPGUZEN-AGCMQPJKSA-N (R)-methylmalonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)[C@@H](C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-AGCMQPJKSA-N 0.000 description 1
- QCHPKSFMDHPSNR-VKHMYHEASA-N (S)-3-aminoisobutyric acid Chemical compound [NH3+]C[C@H](C)C([O-])=O QCHPKSFMDHPSNR-VKHMYHEASA-N 0.000 description 1
- VOKUMXABRRXHAR-UHFFFAOYSA-N 2-methyl-3-oxopropanoic acid Chemical compound O=CC(C)C(O)=O VOKUMXABRRXHAR-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 241000009120 Elymus fibrosus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2003/001463 WO2004091598A1 (en) | 2003-04-18 | 2003-04-18 | Use of beta-aminoisobutyric acid for the treatment of diseases linked to the accumulation of triglycerides and cholesterol |
| PCT/IB2004/001166 WO2004091599A1 (en) | 2003-04-18 | 2004-04-15 | Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523672A true JP2006523672A (ja) | 2006-10-19 |
| JP2006523672A5 JP2006523672A5 (enExample) | 2007-06-07 |
Family
ID=33187198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506481A Withdrawn JP2006523672A (ja) | 2003-04-18 | 2004-04-15 | トリグリセリド及びコレステロールの蓄積に結びつけられる疾病の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060167098A1 (enExample) |
| EP (1) | EP1615630A1 (enExample) |
| JP (1) | JP2006523672A (enExample) |
| AU (1) | AU2003226582A1 (enExample) |
| BR (1) | BRPI0409456A (enExample) |
| CA (1) | CA2526899A1 (enExample) |
| WO (2) | WO2004091598A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013544251A (ja) * | 2010-11-15 | 2013-12-12 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | アミロイド線維形成関連状態を処置するためのジペプチドアナログ |
| JP2019510041A (ja) * | 2016-03-30 | 2019-04-11 | マイクロバイオ カンパニー， リミテッド | 免疫チェックポイントモジュレーターおよび共生微生物叢による発酵産物の併用がん療法 |
| JP2019131488A (ja) * | 2018-01-29 | 2019-08-08 | 静岡県公立大学法人 | Ｖｃａｍ−１発現抑制剤、ｍｃｐ−１発現抑制剤、炎症性疾患改善用組成物、加工食品又は飲料 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367072B2 (en) * | 2006-12-08 | 2013-02-05 | Polifenoles Naturales, S.L. | Composition for treating obesity and method of using the same |
| CN105250256A (zh) * | 2015-10-16 | 2016-01-20 | 南京医科大学 | β-氨基异丁酸在制备抗糖尿病药物中的应用 |
| US20220347141A1 (en) * | 2019-09-17 | 2022-11-03 | Yale University | Methods of treating phosphate concentration disorders with l-baiba |
| AU2022258161B2 (en) * | 2021-04-14 | 2025-05-22 | Nanjing Nutrabuilding Bio-Tech Co., Ltd. | Compositions and methods for promoting glycogen synthase activity and augmenting glycogen storage capability |
| CN117561056A (zh) * | 2021-06-22 | 2024-02-13 | 南京纽邦生物科技有限公司 | 施用β-氨基异丁酸增加间歇性禁食减肥的益处 |
| CN115606809A (zh) * | 2021-10-08 | 2023-01-17 | 南京纽邦生物科技有限公司 | 通过施用β-氨基异丁酸模拟热量限制的生物学益处的方法和组合物 |
| CN116059195A (zh) * | 2022-01-28 | 2023-05-05 | 南京纽邦生物科技有限公司 | 用于提高运动表现或预防或缓解疲劳的组合物和方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4453941A (en) * | 1980-12-29 | 1984-06-12 | Board Of Overseers Of Goshen College | Composition and process for producing pigmentation in hair or skin |
| DE4115468A1 (de) * | 1991-05-11 | 1992-11-12 | Behringwerke Ag | Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien |
| FR2701948B1 (fr) * | 1993-02-22 | 1996-07-26 | Exsymol Sa | Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires. |
| JPH07101984A (ja) * | 1993-09-30 | 1995-04-18 | Suntory Ltd | ペプチド誘導体 |
| JPH107553A (ja) * | 1996-03-21 | 1998-01-13 | Toutoushiyu Seizo Kk | 生体内ラジカル消去剤及び抗潰瘍剤 |
-
2003
- 2003-04-18 AU AU2003226582A patent/AU2003226582A1/en not_active Abandoned
- 2003-04-18 WO PCT/IB2003/001463 patent/WO2004091598A1/en not_active Ceased
-
2004
- 2004-04-15 EP EP04727612A patent/EP1615630A1/en not_active Withdrawn
- 2004-04-15 US US10/553,807 patent/US20060167098A1/en not_active Abandoned
- 2004-04-15 JP JP2006506481A patent/JP2006523672A/ja not_active Withdrawn
- 2004-04-15 WO PCT/IB2004/001166 patent/WO2004091599A1/en not_active Ceased
- 2004-04-15 BR BRPI0409456-5A patent/BRPI0409456A/pt not_active Application Discontinuation
- 2004-04-15 CA CA002526899A patent/CA2526899A1/en not_active Abandoned
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013544251A (ja) * | 2010-11-15 | 2013-12-12 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | アミロイド線維形成関連状態を処置するためのジペプチドアナログ |
| US9630989B2 (en) | 2010-11-15 | 2017-04-25 | Ramot At Tel-Aviv University Ltd. | Dipeptide analogs for treating conditions associated with amyloid fibril formation |
| JP2019510041A (ja) * | 2016-03-30 | 2019-04-11 | マイクロバイオ カンパニー， リミテッド | 免疫チェックポイントモジュレーターおよび共生微生物叢による発酵産物の併用がん療法 |
| JP2022058740A (ja) * | 2016-03-30 | 2022-04-12 | マイクロバイオ カンパニー， リミテッド | 免疫チェックポイントモジュレーターおよび共生微生物叢による発酵産物の併用がん療法 |
| JP7442555B2 (ja) | 2016-03-30 | 2024-03-04 | マイクロバイオ カンパニー， リミテッド | 免疫チェックポイントモジュレーターおよび共生微生物叢による発酵産物の併用がん療法 |
| JP2019131488A (ja) * | 2018-01-29 | 2019-08-08 | 静岡県公立大学法人 | Ｖｃａｍ−１発現抑制剤、ｍｃｐ−１発現抑制剤、炎症性疾患改善用組成物、加工食品又は飲料 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2526899A1 (en) | 2004-10-28 |
| US20060167098A1 (en) | 2006-07-27 |
| WO2004091598A1 (en) | 2004-10-28 |
| AU2003226582A1 (en) | 2004-11-04 |
| EP1615630A1 (en) | 2006-01-18 |
| WO2004091599A1 (en) | 2004-10-28 |
| BRPI0409456A (pt) | 2006-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5057003B2 (ja) | 肥満、高血圧及び脂肪肝の治療用の新規な脂肪類似体 | |
| TWI547278B (zh) | 阿茲海默症及老化腦部之補缺（ａｎａｐｌｅｒｏｔｉｃ）療法 | |
| EP3197429B1 (en) | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals | |
| JP2637712B2 (ja) | ３−グアニジノプロピオン酸を含有する組成物 | |
| WO1993003714A2 (en) | Method for treatment of metabolic disorders | |
| WO2013036104A1 (en) | Infant nutrition for regulating food intake later in life | |
| JP2006523672A (ja) | トリグリセリド及びコレステロールの蓄積に結びつけられる疾病の治療方法 | |
| AU2005251576B2 (en) | Regulator of physiological function of ghrelin and use thereof | |
| JP2018199643A (ja) | リポ多糖を用いた脳機能改善剤、食品及び医薬品 | |
| JPWO2002030418A1 (ja) | 脂質代謝改善用組成物 | |
| RU2375055C2 (ru) | Применение альфа-кетоглутарата и родственных соединений для снижения липидов плазмы | |
| US11504395B2 (en) | Oral pyrophosphate for use in reducing tissue calcification | |
| JP2001240544A (ja) | 抗肥満剤及び脂質代謝改善剤 | |
| Ricciolini et al. | The effect of pivalate treatment of pregnant rats on body mass and insulin levels in the adult offspring | |
| JP2007262017A (ja) | ピペコリン酸含有抗糖尿病組成物 | |
| JPWO2007069744A1 (ja) | メタボリックシンドローム予防・改善用組成物 | |
| JP5008910B2 (ja) | 脂質代謝改善用組成物 | |
| WO2023208925A1 (en) | Nutritional composition for use in preventing programmed obesity in female infants | |
| Team | High PUFA to Saturated Fat Ratio Increase All-Cause Mortality | |
| Aguirre | The Effects of LAT1 Muscle-specific Knockout on Skeletal Muscle Anabolic Responses | |
| CN106604732A (zh) | 二氢胆固醇的用途 | |
| WO2003063853A1 (en) | Compositions for lessening mesenteric fat | |
| KR20070022220A (ko) | 오스페미펜의 생물학적 이용가능성 강화방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070412 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070412 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100809 |